



Crushing nirmatrelvir+ritonavir (Paxlovid®) tablets

Background

Pfizer state in their prescribing information that both nirmatrelvir and ritonavir tablets should be swallowed whole and not chewed, broken, or crushed. [1] This is due to a lack of pharmacokinetic data to support administration in this manner. However, a Phase 1 study with a nirmatrelvir suspension found similar pharmacokinetic parameters to those reported for the tablet. [2] Pfizer have also released information on how to prepare a liquid suspension from nirmatrelvir and ritonavir tablets for administration via enteral tubes, based on an unpublished laboratory study assessing the physiochemical stability of such a formulation. [3]

Recommendation

Given that alternative antivirals may not be as effective as nirmatrelvir+ritonavir, we suggest it is reasonable to crush these tablets for those patients who have trouble swallowing, or who require administration via an enteral tube.

Enteral tubes

- 1. Disperse nirmatrelvir tablet(s) in 10 mL water in an enteral syringe.
- 2. Shake vigorously and then lie the syringe flat for about 3 minutes to allow the tablet(s) to fully disintegrate.
- 3. Crush ritonavir tablet and disperse in 10 mL water in an enteral syringe.
- 4. Shake vigorously and then lie the syringe flat for about 3 minutes to allow the powder to fully disintegrate.
- 5. The resulting liquids are stable for 4 hours but should be administered within 5 minutes of each other.
- 6. Flush with 10 mL water in between each addition and afterwards.

Trouble swallowing

- 1. Crush nirmatrelvir and ritonavir tablets.
- 2. Mix the resulting powder with a small amount of liquid or soft food.

References

- 1. Data sheet: Paxlovid. [Internet]. Pfizer New Zealand Pty Ltd; [cited 2022 Dec 19]. Available
 - https://www.medsafe.govt.nz/profs/Datasheet/p /paxlovidtab.pdf
- 2. Innovative Randomized Phase 1 Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir | medRxiv [Internet]. [cited 2022 Dec 19]. Available from: https://www.medrxiv.org/content/10.1101/2022 .02.08.22270649v1
- 3. Pfizer Medical Information. PF-07321332 (nirmatrelvir)/Ritonavir Administration via Enteral Feeding Tubes. 2022.